PubRank

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)

Clinical Trial ID NCT01154140

PubWeight™ 46.83‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01154140

Top papers

Rank Title Journal Year PubWeight™‹?›
1 First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014 10.91
2 Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol 2015 2.26
3 Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol 2012 1.97
4 Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015 1.67
5 Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011 1.65
6 Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 2011 1.57
7 ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014 1.48
8 Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012 1.45
9 Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011 1.31
10 Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015 1.29
11 Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013 1.22
12 Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014 1.19
13 The evolving genomic classification of lung cancer. J Pathol 2014 1.08
14 Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014 1.05
15 Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012 1.01
16 New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res 2011 1.01
17 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
18 Novel agents in development for advanced non-small cell lung cancer. Ther Adv Med Oncol 2014 0.95
19 Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol 2014 0.93
20 Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014 0.92
21 Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. Onco Targets Ther 2015 0.90
22 Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 2013 0.89
23 Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. Cancer Manag Res 2013 0.88
24 EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3. Oncoimmunology 2015 0.86
25 Crizotinib: A comprehensive review. South Asian J Cancer 2013 0.85
26 ALK and NSCLC: Targeted therapy with ALK inhibitors. F1000 Med Rep 2011 0.85
27 Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med 2012 0.82
28 Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2013 0.81
29 Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer 2012 0.80
30 Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol 2013 0.79
31 Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells. Oncotarget 2016 0.79
32 Crizotinib in the treatment of non-small-cell lung carcinoma. Contemp Oncol (Pozn) 2013 0.78
33 Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Rev Anticancer Ther 2012 0.76
34 ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget 2016 0.76
35 Crizotinib: a breakthrough for targeted therapies in lung cancer. J Adv Pract Oncol 2012 0.75
36 Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. Drugs Future 2011 0.75
Next 100